Abstract
The 21-gene recurrence score (RS) assay is included in treatment guidelines for predicting adjuvant chemotherapy benefit for early-stage breast cancer patients with hormone-receptor (HR) positive disease. However, there has been no consideration regarding racial difference of that predictive value, although the assay had developed based on mainly Western women. This study aimed to demonstrate the racial differences in the predictive values of 21-gene RS assay.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
